The lab is focusing on signaling to develop targeted therapies. The lab seeks to identify how pathological activation of the Hippo pathway effector yes-associated protein (YAP) drives cholangiocarcinoma growth and chemotherapy resistance. The lab also is using preclinical models to test novel therapeutic strategies for this deadly disease.
Dr. Gores' lab is studying the mechanisms that govern the development of metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis Specifically, the lab is studying how cell-to-cell communication influences disease progression.